Center for Vulvovaginal Disorders   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Washington D.C. United States

Organization Overview

First Clinical Trial
2006
NCT00393263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Center for Vulvovaginal Disorders | The Center for Vulvovaginal Disorders

Active Ingredients

Drugs in Phase 3 Trials (1)

prasterone (intrarosa) (1 trial)

Drugs in Phase 2 Trials (3)

clobetasol (dermovate) (1 trial)

pimecrolimus (elidel) (1 trial)

platelet-rich plasma (3 trials)

Drugs in Other Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Dyspareunia (Phase 3)

Lichen Sclerosus et Atrophicus (Phase 2)

Sexual Dysfunctions, Psychological (Phase 2)

Syndrome (Phase 3)

Vulvar Lichen Sclerosus (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 5